Antitoxin treatment for liver abscess caused by Clostridium perfringens
Toru Hifumi, Yuichi Koido, Motohide Takahashi, Akihiko Yamamoto
Clin Mol Hepatol. 2013;19(1):97-98.   Published online 2013 Mar 25     DOI: https://doi.org/10.3350/cmh.2013.19.1.97
Citations to this article as recorded by Crossref logo
What is the future beyond examining the pathogenicity of the causative organisms in severe infections?: antibody therapy
Toru Hifumi
Journal of the Japanese Society of Intensive Care Medicine.2023; 30(4): 223.     CrossRef
Spontaneous Non-Traumatic Clostridium perfringens Sepsis
Toru Hifumi
Japanese Journal of Infectious Diseases.2020; 73(3): 177.     CrossRef
Severe sepsis caused by a gas-forming Clostridium perfringens and Klebsiella variicola liver abscess following total pancreatectomy
Stig Søgaard Dahl, Morten Thorsteinsson, Trine-Lise Lambine, Luit Penninga
BMJ Case Reports.2020; 13(10): e238896.     CrossRef
Combined therapy with gas gangrene antitoxin and recombinant human soluble thrombomodulin for Clostridium perfringens sepsis in a rat model
Toru Hifumi, Daisuke Nakano, Joe Chiba, Motohide Takahashi, Akihiko Yamamoto, Yoshihide Fujisawa, Kenya Kawakita, Yasuhiro Kuroda, Akira Nishiyama
Toxicon.2018; 141: 112.     CrossRef
Clinical serum therapy
Toru Hifumi
Journal of the Japanese Society of Intensive Care Medicine.2018; 25(4): 235.     CrossRef
Clinical Serum Therapy: Benefits, Cautions, and Potential Applications
Toru Hifumi, Akihiko Yamamoto, Manabu Ato, Kyoko Sawabe, Kazunori Morokuma, Nobuya Morine, Yutaka Kondo, Eiichiro Noda, Atsushi Sakai, Jin Takahashi, Kazuo Umezawa
The Keio Journal of Medicine.2017; 66(4): 57.     CrossRef